DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma
Condition(s):Leukemia; LymphomaLast Updated:December 2, 2017Completed
Hide Studies Not Open or Pending
Condition(s):Leukemia; LymphomaLast Updated:December 2, 2017Completed
Condition(s):LymphomaLast Updated:October 4, 2012Completed
Condition(s):LymphomaLast Updated:November 30, 2011Completed
Condition(s):LymphomaLast Updated:December 15, 2016Completed
Condition(s):Graft Versus Host Disease; LymphomaLast Updated:July 20, 2015Completed
Condition(s):Lymphoma; Unspecified Adult Solid Tumor, Protocol SpecificLast Updated:March 8, 2012Completed
Condition(s):LymphomaLast Updated:June 1, 2012Completed
Condition(s):Leukemia; LymphomaLast Updated:January 10, 2014Unknown status
Condition(s):LymphomaLast Updated:August 7, 2013Unknown status
Condition(s):LymphomaLast Updated:November 29, 2017Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.